Natco Wins Patent Battle, Cleared to Launch Generic Risdiplam for SMA in India
Natco Pharma has won a significant legal victory in India, enabling it to launch a generic version of risdiplam, a treatment for spinal muscular atrophy (SMA). In a ruling by an appellate bench of the Delhi High Court, the court dismissed a plea by Roche seeking to block Natco’s launch, thereby allowing the Indian company to proceed with its version.
Natco To Launch Generic Risdiplam | 10/10/2025 | By Darshana | 116
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy